Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STRATA Skin Sciences, Inc. Director's Dealing 2015

Aug 24, 2015

35146_dirs_2015-08-24_55d53c5b-6507-4d06-bc7e-0c093a8912ee.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MELA SCIENCES, INC. /NY (MELA)
CIK: 0001051514
Period of Report: 2015-08-11

Reporting Person: Broadfin Capital, LLC (10% Owner)
Reporting Person: Broadfin Healthcare Master Fund Ltd (10% Owner)
Reporting Person: KOTLER KEVIN (10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1274297 Direct
Common Stock 1274297 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Common Stock Warrant $7.40 2019-02-05 Common Stock, $0.001 par value per share (432432) Direct
Common Stock Warrant $7.40 2019-02-05 Common Stock, $0.001 par value per share (432432) Indirect
Common Stock Warrant $2.45 2019-07-24 Common Stock, $0.001 par value per share (1267849) Direct
Common Stock Warrant $2.45 2019-07-24 Common Stock, $0.001 par value per share (1267849) Indirect
Common Stock Warrant $2.45 2016-01-24 Common Stock, $0.001 par value per share (1559454) Direct
Common Stock Warrant $2.45 2016-01-24 Common Stock, $0.001 par value per share (1559454) Indirect
Common Stock Warrant $0.75 2020-06-22 Common Stock, $0.001 par value per share (1500000) Direct
Common Stock Warrant $0.75 2020-06-22 Common Stock, $0.001 par value per share (1500000) Indirect
Senior Convertible Debenture $ 2019-07-24 Common Stock, $0.001 par value per share (377177) Direct
Senior Convertible Debenture $ 2019-07-24 Common Stock, $0.001 par value per share (377177) Indirect
Senior Convertible Debenture $ 2020-06-22 Common Stock, $0.001 par value per share (20000000) Direct
Senior Convertible Debenture $ 2020-06-22 Common Stock, $0.001 par value per share (20000000) Indirect

Footnotes

F1: The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

F2: Broadfin Capital, LLC shall not have the right to exercise the Warrants to purchase shares of common stock, to the extent that, after giving effect to the conversion or exercise, Broadfin Capital, LLC (directly or indirectly) would beneficially own in excess of 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of the Warrants held by Broadfin Capital, LLC.

F3: These debentures (the "Debentures") are convertible into shares of common stock at a conversion price of $2.565 per common share of the Issuer. The Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock of the Issuer.

F4: These Debentures are convertible into shares of common stock at a conversion price of $0.75 per share of the Issuer. The Debentures bear interest at the rate of 2.25% per year. Under the terms of the Debentures, the issuances of shares of the common stock upon conversion are subject to the approval by the Issuer's stockholders.